-
公开(公告)号：US08394964B2
公开(公告)日：2013-03-12
申请号：US12969371
申请日：2010-12-15
IPC分类号： C07D213/75
CPC分类号： C07D213/75
摘要： Described herein are novel methods of preparing a compound of Formula II or a pharmaceutically acceptable salt thereof. In some embodiments, the method is for preparing betrixaban or a pharmaceutically acceptable salt thereof. Also described are compositions comprising substantially pure betrixaban free base or salt thereof.
-
公开(公告)号：US20110319627A1
公开(公告)日：2011-12-29
申请号：US12969371
申请日：2010-12-15
IPC分类号： C07D213/75
CPC分类号： C07D213/75
摘要： Described herein are novel methods of preparing a compound of Formula II or a pharmaceutically acceptable salt thereof. In some embodiments, the method is for preparing betrixaban or a pharmaceutically acceptable salt thereof. Also described are compositions comprising substantially pure betrixaban free base or salt thereof.
摘要翻译： 本文描述了制备式II化合物或其药学上可接受的盐的新方法。 在一些实施方案中，该方法用于制备betrixaban或其药学上可接受的盐。 还描述了包含基本上纯的双倍他卡巴游离碱或其盐的组合物。
-
公开(公告)号：US20210220290A1
公开(公告)日：2021-07-22
申请号：US17151121
申请日：2021-01-16
摘要： The invention discloses a composition comprising not less than 20% w/w bisdemethoxycurcumin for regeneration of alveolar cells damaged in emphysematous conditions and for the therapeutic management of chronic obstructive pulmonary disease and acute respiratory distress syndrome. The composition further comprises 10-35% w/w demethoxycurcumin and 10-45% w/w curcumin. The composition is very suitable for treating COPD and ARDS due to viral infections, specifically COVID 19 and for improving lung function during prognosis.
-
4.发明授权Composition comprising scirpusin A and scirpusin B and anti-adipogenesis/anti-obesity potential thereof 有权组合物，其包含鞘氨醇蛋白A和柔霉素B及其抗脂肪生成/抗肥胖潜力公开(公告)号：US09387193B2
公开(公告)日：2016-07-12
申请号：US13944634
申请日：2013-07-17
申请人： Muhammed Majeed , Kalyanam Nagabhushanam , Douglas Kalman , Beena Bhat , Priti Vaidyanathan , Sarang Bani , Anjali Pandey
发明人： Muhammed Majeed , Kalyanam Nagabhushanam , Douglas Kalman , Beena Bhat , Priti Vaidyanathan , Sarang Bani , Anjali Pandey
IPC分类号： A61K31/343 , A61K36/8905
CPC分类号： A61K31/343 , A61K36/8905
摘要： Disclosed is a composition comprising scirpusin A and scirpusin B and anti-obesity potential thereof. Also disclosed are methods of inhibiting adipogenesis using a composition comprising scirpusin A and scirpusin B. The present invention also disclosed methods of therapeutically managing obesity in mammals using a composition comprising scirpusin A and scirpusin B. Still further, the present invention also relates to a method of obtaining compositions comprising A. scirpusin A and scirpusin B and B. piceatannol and its dimers scirpusin A and scirpusin B through bioactivity guided fractionation of the rhizomes of Cyperus rotundus.
摘要翻译： 本发明公开了一种组合物，其中含有柔霉素A和柔霉素B及其抗肥胖潜力。 还公开了使用包含灵敏蛋白A和柔红霉素B的组合物来抑制脂肪生成的方法。本发明还公开了使用包含巩螺素A和柔红霉素B的组合物来治疗哺乳动物肥胖的方法。此外，本发明还涉及一种方法 通过生物活性引导分离莎草莎草根茎，获得包含A.Scirpusin A和Scirpusin B和B.piceatannol及其二聚体scirpusin A和scirpusin B的组合物。
-
公开(公告)号：US08946269B2
公开(公告)日：2015-02-03
申请号：US13223023
申请日：2011-08-31
申请人： Vincent R. Capodanno , Liam Corcoran , Michael McNevin , Itzia Zoraida Arroyo , Robert M. Wenslow , Richard G. Ball , Eric L. Margelefsky , Timothy K. Maher , Anjali Pandey
发明人： Vincent R. Capodanno , Liam Corcoran , Michael McNevin , Itzia Zoraida Arroyo , Robert M. Wenslow , Richard G. Ball , Eric L. Margelefsky , Timothy K. Maher , Anjali Pandey
IPC分类号： A61K31/44 , C07D213/75
CPC分类号： A61K31/44 , C07D213/75
摘要： Provided herein are crystalline forms of a maleate salt of betrixaban, compositions and methods of preparation or use thereof.
摘要翻译： 本文提供的是betrixaban的马来酸盐的结晶形式，组合物及其制备方法或用途。
-
6.发明申请COMBINATION THERAPY OF 4-(3-(2H-1,2,3-TRIAZO-2-YL)PHENYLAMINO)-2-((1R,2S)-2-AMINOCYCLOHEXYLAMINO)PYRIMIDINE-5-CARBOXAMIDE AND FLUDARABINE 审中-公开4-（3-（2H-1,2,3-三唑-2-基）苯基氨基）-2 - （（1R，2S）-2-氨基甲酰氧基]氨基] -5-羧酰胺和氟尿嘧啶的组合治疗公开(公告)号：US20130252917A1
公开(公告)日：2013-09-26
申请号：US13823710
申请日：2011-09-30
申请人： Uma Sinha , Anjali Pandey
发明人： Uma Sinha , Anjali Pandey
IPC分类号： A61K31/7076 , A61K31/506
CPC分类号： A61K31/7076 , A61K31/506 , A61K2300/00
摘要： The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing 4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-(1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide, or a pharmaceutically acceptable salt thereof, and fludarabine for the treatment of cell proliferative disorders, such as undesired acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL); mantle cell lymphoma, acute lymphocytic leukemia (ALL), follicular lymphoma, Burkitt's lymphoma, small Lymphocytic Lymphoma (SLL) and multiple myeloma.
摘要翻译： 本发明涉及药物组合物和使用含有4-（3-（2H-1,2,3-三唑-2-基）苯基氨基）-2-（1R，2S）-2-氨基环己基氨基） 嘧啶-5-甲酰胺或其药学上可接受的盐，和氟达拉滨用于治疗细胞增殖性疾病，例如不期望的急性骨髓性白血病（AML），慢性淋巴细胞白血病（CLL），非霍奇金淋巴瘤（NHL），包括弥漫性 大B细胞淋巴瘤（DLBCL）; 套细胞淋巴瘤，急性淋巴细胞白血病（ALL），滤泡淋巴瘤，伯基特淋巴瘤，小淋巴细胞淋巴瘤（SLL）和多发性骨髓瘤。
-
7.发明申请INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR 审中-公开直接作用和可逆的P2Y12抑制剂的口服和口服剂量公开(公告)号：US20120009172A1
公开(公告)日：2012-01-12
申请号：US13235305
申请日：2011-09-16
申请人： Daniel D. Gretler , Pamela B. Conley , Patrick Andre , Athiwat Hutchaleelaha , David R. Phillips , Anjali Pandey , Robert M. Scarborough , Carroll Anna Crew Scarborough , Wolin Huang
发明人： Daniel D. Gretler , Pamela B. Conley , Patrick Andre , Athiwat Hutchaleelaha , David R. Phillips , Anjali Pandey , Robert M. Scarborough , Carroll Anna Crew Scarborough , Wolin Huang
IPC分类号： A61K38/45 , A61K38/48 , A61P9/00 , A61K31/517 , C07D409/12 , A61P7/00 , A61K38/46 , A61K31/60
CPC分类号： A61K31/517 , A61K31/216 , A61K2300/00
摘要： The invention provides methods and compositions for rapid and reversible inhibition of platelet aggregation in human subjects in need thereof by administering compounds of the formula: alone or in combination with a second agent which can be aspirin or a thrombolytic agent.
摘要翻译： 本发明提供了通过施用下式的化合物单独或与可以是阿司匹林或溶栓剂的第二药剂组合来快速和可逆地抑制有需要的人受试者血小板聚集的方法和组合物。
-
公开(公告)号：US08063077B2
公开(公告)日：2011-11-22
申请号：US12777956
申请日：2010-05-11
申请人： Yonghong Song , Zhaozhong J. Jia , Robert M. Scarborough , Carroll Scarborough, legal representative , Anjali Pandey
IPC分类号： A61K31/4412 , C07D401/14
CPC分类号： C07D401/14 , C07D409/14 , C07D413/14 , C07D417/14
摘要： The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to intermediates used in making such compounds, pharmaceutical compositions containing such a compound, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.
摘要翻译： 本发明涉及作为因子Xa抑制剂的式（I）化合物及其药学上可接受的盐，酯和前药。 本发明还涉及用于制备这种化合物的中间体，含有这种化合物的药物组合物，预防或治疗许多不希望的血栓形成特征的病症的方法和抑制血液样品凝固的方法。
-
公开(公告)号：US08063058B2
公开(公告)日：2011-11-22
申请号：US12386525
申请日：2009-04-16
申请人： Zhaozhong J. Jia , Chandrasekar Venkataramani , Wolin Huang , Mukund Mehrotra , Yonghong Song , Qing Xu , Shawn M. Bauer , Jack W. Rose , Brian Kane , Anjali Pandey
发明人： Zhaozhong J. Jia , Chandrasekar Venkataramani , Wolin Huang , Mukund Mehrotra , Yonghong Song , Qing Xu , Shawn M. Bauer , Jack W. Rose , Brian Kane , Anjali Pandey
IPC分类号： A01N43/54 , A61K31/505 , C07D401/00 , C07D403/00 , C07D405/00 , C07D409/00 , C07D411/00 , C07D413/00 , C07D417/00 , C07D419/00
CPC分类号： A61K31/506 , C07D239/48 , C07D401/12 , C07D403/12 , C07D407/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D471/04 , C07D487/04
摘要： The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.
摘要翻译： 本发明涉及作为syk激酶抑制剂的式I-V化合物及其互变异构体或其药学上可接受的盐，酯和前体药物。 本发明还涉及用于制备这种化合物的中间体，这种化合物的制备，含有这种化合物的药物组合物，抑制syk激酶活性的方法，抑制血小板聚集的方法，以及预防或治疗数字的方法 至少部分通过syk激酶活性介导的病症，例如不期望的血栓形成和非霍奇金淋巴瘤。
-
公开(公告)号：US08022071B2
公开(公告)日：2011-09-20
申请号：US11959341
申请日：2007-12-18
申请人： Anjali Pandey , Robert M. Scarborough , Kenji Matsuno , Michio Ichimura , Yuji Nomoto , Shinichi Ide , Eiji Tsukuda , Junko Sasaki , Shoji Oda
发明人： Anjali Pandey , Robert M. Scarborough , Kenji Matsuno , Michio Ichimura , Yuji Nomoto , Shinichi Ide , Eiji Tsukuda , Junko Sasaki , Shoji Oda
IPC分类号： A61K31/5377 , A61K31/517
CPC分类号： C07D401/12 , C07D239/94 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12
摘要： The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
摘要翻译： 本发明涉及对抑制这种激酶活性的激酶磷酸化具有抑制活性的含氮杂环化合物及其药学上可接受的盐。 本发明还涉及通过抑制激酶的磷酸化来抑制哺乳动物的激酶和治疗疾病状态的方法。 在一个特定方面，本发明提供了抑制PDGF受体的磷酸化以阻止异常细胞生长和细胞游动的含氮杂环化合物及其药学上可接受的盐，以及预防或治疗细胞增殖性疾病如动脉硬化，血管 重建，癌症和肾小球硬化症。
-
-
-
-
-
-
-
-
-
搜索结果
115 条记录 (耗时 0.032 秒)